Endocrine Ophthalmopathy in a Patient under Continuous Immunosuppressive Therapy after Cardiac Transplantation
- 1 December 1995
- journal article
- case report
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 5 (6) , 477-480
- https://doi.org/10.1089/thy.1995.5.477
Abstract
We present the case of a female patient who has been on immunosuppressive therapy consisting of cyclosporin A and prednisolone for 9 years because of heterotopic (auxiliary) heart transplantation in 1984. In 1992 the patient developed Graves' disease followed by endocrine ophthalmopathy class IV 1 year later. To our knowledge this is the first report on Graves' disease with subsequent severe endocrine ophthalmopathy in a patient under immunosuppressive treatment with cyclosporin A and prednisolone in doses that effectively prevent heart transplant rejection. Prednisolone, which is used as a first line treatment of endocrine ophthalmopathy, and cyclosporin A, both inhibit T cell function. However, in this patient they were not effective in preventing the development of Graves' disease with subsequent endocrine ophthalmopathy, both of which are autoimmune diseases.Keywords
This publication has 5 references indexed in Scilit:
- Pathogenesis of Graves' OphthalmopathyNew England Journal of Medicine, 1993
- Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathyThe Lancet, 1993
- Prednisone and Cyclosporine in the Treatment of Severe Graves' OphthalmopathyNew England Journal of Medicine, 1989
- Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.British Journal of Ophthalmology, 1989
- Modification of the Classification of the Eye Changes of Graves' Disease: Recommendations of the Ad Hoc Committee of The American Thyroid AssociationJournal of Clinical Endocrinology & Metabolism, 1977